For those seeking long-term weight management solutions, these medications offer a strong option under medical guidance
Kazda CM, Garhyan P, Kelly RP et al (2015) A randomized, double-blind, placebo-controlled phase 2 study of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes
And dont stress about perfection, Zimmermann says
Your healthcare provider may need to adjust other diabetes medications, such as increasing metformin doses, adding SGLT2 inhibitors or DPP-4 inhibitors, or adjusting insulin regimens
This guide is here to help you feel informed, empowered, and supported on your GLP-1 journey
Retatrutide: The Triple Receptor Agonist That May Surpass Semaglutide and Tirzepatide At a glance Drug class / GLP-1, GIP, and glucagon triple receptor agonist Approval status / Investigational